R&D News | pharmaphorum

News

Endeavor raises $132.5m for fibrosis, cancer drugs

Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi

News

Roche says it has shed 20% of NMEs from its pipeline

Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipel

News

Xaira Therapeutics co-founder Dr David Baker

Enter Xaira, with $1bn for its AI in drug discovery platform

Any new company wanting to make waves in applying artificial intelligence to drug discovery will need deep pockets and a top-tier science and management team – and startup

News

Sanofi’s oral BTK programme gets back on track

Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune

News

Shakeup at BenevolentAI continues with job, programme cuts

BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third

News

With $75m cash injection, SynOx plans ph3 rare tumour trial

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into ph

Endeavor raises $132.5m for fibrosis, cancer drugs

Roche says it has shed 20% of NMEs from its pipeline

Enter Xaira, with $1bn for its AI in drug discovery platform

Sanofi’s oral BTK programme gets back on track

Shakeup at BenevolentAI continues with job, programme cuts

With $75m cash injection, SynOx plans ph3 rare tumour trial

Jazz and Lilly cancer drugs cleared for use by NHS

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks